Dashboard
Poor Management Efficiency with a low ROCE of 20.10%
- The company has been able to generate a Return on Capital Employed (avg) of 20.10% signifying low profitability per unit of total capital (equity and debt)
Poor long term growth as Net Sales has grown by an annual rate of -4.77% and Operating profit at -145.81% over the last 5 years
The company has declared negative results for the last 6 consecutive quarters
With ROE of 0.91%, it has a fair valuation with a 2.21 Price to Book Value
Underperformed the market in the last 1 year
Stock DNA
Pharmaceuticals & Biotechnology
CNY 4,990 Million (Small Cap)
243.00
NA
0.00%
-0.69
0.91%
2.21
Total Returns (Price + Dividend) 
Hubei Biocause Heilen Pharmaceutical Co., Ltd. for the last several years.
Risk Adjusted Returns v/s 
News

Hubei Biocause Soars 22% to Day High of CNY 15.74 Amid Strong Performance
Hubei Biocause Heilen Pharmaceutical Co., Ltd. has seen notable stock activity, rising significantly today and over the past week. Despite a strong one-year performance, the company faces challenges, including a low Return on Capital Employed and declining net sales, alongside six consecutive quarters of negative results.
Read More Announcements 
Corporate Actions 
Quality key factors 
Valuation key factors
Technicals key factors
Shareholding Snapshot
Shareholding Compare (%holding) 
Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY
YoY Growth in quarter ended Jun 2025 is 16.14% vs -51.61% in Jun 2024
YoY Growth in quarter ended Jun 2025 is -73.63% vs -57.46% in Jun 2024
Annual Results Snapshot (Consolidated) - Dec'24
YoY Growth in year ended Dec 2024 is -32.80% vs 28.59% in Dec 2023
YoY Growth in year ended Dec 2024 is -48.04% vs 39.98% in Dec 2023






